CN1132845C - 获得具有正确键合的胱氨酸键的胰岛素前体的改进的方法 - Google Patents

获得具有正确键合的胱氨酸键的胰岛素前体的改进的方法 Download PDF

Info

Publication number
CN1132845C
CN1132845C CN98117909A CN98117909A CN1132845C CN 1132845 C CN1132845 C CN 1132845C CN 98117909 A CN98117909 A CN 98117909A CN 98117909 A CN98117909 A CN 98117909A CN 1132845 C CN1132845 C CN 1132845C
Authority
CN
China
Prior art keywords
amino
insulin
acid residue
peptide
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN98117909A
Other languages
English (en)
Chinese (zh)
Other versions
CN1209437A (zh
Inventor
F-J·鲁伯洛德
R·凯勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Hoechst Marion Roussel Deutschland GmbH
Aventis Pharma Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Marion Roussel Deutschland GmbH, Aventis Pharma Deutschland GmbH filed Critical Hoechst Marion Roussel Deutschland GmbH
Publication of CN1209437A publication Critical patent/CN1209437A/zh
Application granted granted Critical
Publication of CN1132845C publication Critical patent/CN1132845C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/12—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by hydrolysis, i.e. solvolysis in general
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN98117909A 1997-08-18 1998-08-17 获得具有正确键合的胱氨酸键的胰岛素前体的改进的方法 Expired - Lifetime CN1132845C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19735711A DE19735711C2 (de) 1997-08-18 1997-08-18 Verfahren zur Herstellung eines Vorläufers von Insulin oder Insulinderivaten mit korrekt verbundenen Cystinbrücken
DE19735711.3 1997-08-18

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN2006101000625A Division CN101186940B (zh) 1997-08-18 1998-08-17 获得具有正确键合的胱氨酸键的胰岛素或胰岛素衍生物的方法
CN031523307A Division CN1483831B (zh) 1997-08-18 1998-08-17 获得具有正确键合的胱氨酸键的胰岛素或胰岛素衍生物的方法

Publications (2)

Publication Number Publication Date
CN1209437A CN1209437A (zh) 1999-03-03
CN1132845C true CN1132845C (zh) 2003-12-31

Family

ID=7839275

Family Applications (3)

Application Number Title Priority Date Filing Date
CN98117909A Expired - Lifetime CN1132845C (zh) 1997-08-18 1998-08-17 获得具有正确键合的胱氨酸键的胰岛素前体的改进的方法
CN031523307A Expired - Lifetime CN1483831B (zh) 1997-08-18 1998-08-17 获得具有正确键合的胱氨酸键的胰岛素或胰岛素衍生物的方法
CN2006101000625A Expired - Lifetime CN101186940B (zh) 1997-08-18 1998-08-17 获得具有正确键合的胱氨酸键的胰岛素或胰岛素衍生物的方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN031523307A Expired - Lifetime CN1483831B (zh) 1997-08-18 1998-08-17 获得具有正确键合的胱氨酸键的胰岛素或胰岛素衍生物的方法
CN2006101000625A Expired - Lifetime CN101186940B (zh) 1997-08-18 1998-08-17 获得具有正确键合的胱氨酸键的胰岛素或胰岛素衍生物的方法

Country Status (20)

Country Link
US (3) US5986048A (https=)
EP (2) EP0906918B1 (https=)
JP (1) JP4291900B2 (https=)
KR (2) KR100537842B1 (https=)
CN (3) CN1132845C (https=)
AR (1) AR016821A1 (https=)
AT (2) ATE217012T1 (https=)
AU (1) AU744824B2 (https=)
BR (2) BRPI9816233B8 (https=)
CA (1) CA2245151C (https=)
CZ (1) CZ295679B6 (https=)
DE (3) DE19735711C2 (https=)
DK (2) DK0980874T3 (https=)
ES (2) ES2177178T3 (https=)
HU (2) HU228161B1 (https=)
ID (1) ID20717A (https=)
PL (1) PL191901B1 (https=)
PT (2) PT980874E (https=)
RU (2) RU2205836C2 (https=)
TR (1) TR199801587A2 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19735711C2 (de) 1997-08-18 2001-04-26 Aventis Pharma Gmbh Verfahren zur Herstellung eines Vorläufers von Insulin oder Insulinderivaten mit korrekt verbundenen Cystinbrücken
DE19930676B4 (de) * 1999-07-02 2006-01-19 Sanofi-Aventis Deutschland Gmbh Verfahren zur Stabilisierung von Insulin, Insulinderivaten und/oder deren Vorläufer in komplexen Mischungen bei deren Lagerung in wäßrigen Lösungsmitteln
EP1242610A1 (en) * 1999-12-22 2002-09-25 Novo Nordisk A/S Method for extractive refolding of scrambledsingle-chain polypeptides
US20030212248A1 (en) * 2000-07-12 2003-11-13 Furman Thomas Charles Process to increase protein stability
DE10235168A1 (de) * 2002-08-01 2004-02-12 Aventis Pharma Deutschland Gmbh Verfahren zur Reinigung von Preproinsulin
DE102004015965A1 (de) * 2004-04-01 2005-10-20 Aventis Pharma Gmbh Verfahren zur Gewinnung von Insulinen durch verbesserte Luftbegasung der Faltung
BRPI0621124A2 (pt) 2005-12-22 2011-11-29 Genentech Inc métodos para recuperação de uma proteìna de ligação à heparina
AR062069A1 (es) * 2006-07-14 2008-10-15 Genentech Inc Replegado de proteinas recombinantes
EP2174140B1 (en) * 2007-07-03 2016-01-13 Amgen Inc. Calculation of protein concentration using inclusion body dry weight
RU2451750C2 (ru) * 2007-09-24 2012-05-27 Общество С Ограниченной Ответственностью "Герофарм" Способ получения рекомбинантного с-пептида проинсулина человека
MY152979A (en) 2008-01-09 2014-12-15 Sanofi Aventis Deutschland Novel insulin derivatives having an extremely delayed time-action profile
JP5677938B2 (ja) * 2008-04-30 2015-02-25 ウォックハート リサーチ センター インシュリンの再折りたたみ方法
RS59913B1 (sr) 2008-10-17 2020-03-31 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
PT3345593T (pt) 2009-11-13 2023-11-27 Sanofi Aventis Deutschland Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
MY180661A (en) 2009-11-13 2020-12-04 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
PL2611458T3 (pl) 2010-08-30 2017-02-28 Sanofi-Aventis Deutschland Gmbh Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US12157766B2 (en) * 2012-08-05 2024-12-03 Absci Corporation Cytoplasmic expression system
US10421795B2 (en) 2012-12-17 2019-09-24 Merck Sharp & Dohme Corp. Process for purifying insulin and analogues thereof
DK2963056T3 (da) * 2013-02-26 2020-02-17 Hanmi Pharm Ind Co Ltd Insulinanalog og anvendelse deraf
CN103694339B (zh) * 2013-12-04 2017-10-13 珠海联邦制药股份有限公司 一种甘精胰岛素前体的复性方法
WO2015138548A1 (en) 2014-03-14 2015-09-17 Merck Sharp & Dohme Corp. Purifying insulin using cation exchange and reverse phase chromatography in the presence of an organic modifier and elevated temperature
EP3229828B1 (en) 2014-12-12 2023-04-05 Sanofi-Aventis Deutschland GmbH Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
CN104911203A (zh) * 2015-06-30 2015-09-16 成都易胜科生物科技有限公司 一种重组人胰岛素的工业制备方法
EP3344651B1 (en) 2015-09-02 2022-03-02 Merck Sharp & Dohme Corp. A process for obtaining insulin with correctly formed disulfide bonds
US10689430B2 (en) 2016-05-25 2020-06-23 Merck Sharp & Dohme Corp. Insulin receptor partial agonists
WO2018018613A1 (zh) 2016-07-29 2018-02-01 广东东阳光药业有限公司 一种提高抗体纯度的细胞培养基和培养方法
CN113773400B (zh) * 2020-06-09 2023-08-18 宁波鲲鹏生物科技有限公司 一种门冬胰岛素衍生物及其应用
CN113773391B (zh) * 2020-06-09 2023-10-20 宁波鲲鹏生物科技有限公司 一种门冬胰岛素的制备方法
CN113773396A (zh) * 2020-06-10 2021-12-10 宁波鲲鹏生物科技有限公司 一种地特胰岛素衍生物及其应用
JP7749397B2 (ja) * 2021-09-30 2025-10-06 キヤノン株式会社 超音波ファントム及び超音波ファントムの製造方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ199391A (en) * 1981-01-02 1985-12-13 Genentech Inc Chimeric polypeptides comprising a proinsulin sequence,and preparation by recombinant dna technique;production of human insulin
DE3501641A1 (de) * 1985-01-19 1986-07-24 Hoechst Ag, 6230 Frankfurt Verfahren zur gewinnung von insulin-vorlaeufern aus reaktionsgemischen, die bei der faltung von insulin-vorlaeufern aus den entsprechenden s-sulfonaten anfallen
GR1005153B (el) * 1989-08-29 2006-03-13 The General Hospital Corporation Πρωτεινες συντηξεως, παρασκευη τους και χρηση τους.
RU2045535C1 (ru) * 1991-06-18 1995-10-10 Институт биоорганической химии им.М.М.Шемякина и Ю.А.Овчинникова РАН Способ получения проинсулина человека
ATE148710T1 (de) * 1992-12-02 1997-02-15 Hoechst Ag Verfahren zur gewinnung von proinsulin mit korrekt verbundenen cystinbrücken
DE4405179A1 (de) * 1994-02-18 1995-08-24 Hoechst Ag Verfahren zur Gewinnung von Insulin mit korrekt verbundenen Cystinbrücken
RU2081122C1 (ru) * 1994-06-16 1997-06-10 Институт биоорганической химии им.М.М.Шемякина и Ю.А.Овчинникова РАН Способ выделения и очистки инсулина или его биотехнологических предшественников
BR9408638A (pt) * 1994-12-29 2004-09-21 Bio Technology General Corp Geração de insulina humana
DE19735711C2 (de) 1997-08-18 2001-04-26 Aventis Pharma Gmbh Verfahren zur Herstellung eines Vorläufers von Insulin oder Insulinderivaten mit korrekt verbundenen Cystinbrücken

Also Published As

Publication number Publication date
EP0980874A1 (de) 2000-02-23
CZ259898A3 (cs) 1999-03-17
KR20050067371A (ko) 2005-07-01
RU2302882C2 (ru) 2007-07-20
AR016821A1 (es) 2001-08-01
DE59804121D1 (de) 2002-06-20
ATE217012T1 (de) 2002-05-15
CZ295679B6 (cs) 2005-09-14
US6380355B1 (en) 2002-04-30
CN1483831A (zh) 2004-03-24
DE19735711A1 (de) 1999-02-25
ID20717A (id) 1999-02-18
KR100574580B1 (ko) 2006-04-28
BRPI9816233B1 (pt) 2016-09-27
DK0906918T3 (da) 2002-09-09
PL328108A1 (en) 1999-03-01
CN1209437A (zh) 1999-03-03
JP4291900B2 (ja) 2009-07-08
BRPI9816233B8 (pt) 2021-05-25
PL191901B1 (pl) 2006-07-31
BR9803755A (pt) 2000-03-28
AU8076398A (en) 1999-02-25
CN101186940A (zh) 2008-05-28
AU744824B2 (en) 2002-03-07
KR19990023651A (ko) 1999-03-25
PT980874E (pt) 2002-10-31
CN101186940B (zh) 2012-02-08
EP0906918B1 (de) 2002-05-15
DE19735711C2 (de) 2001-04-26
EP0906918A3 (de) 1999-08-11
ATE217636T1 (de) 2002-06-15
DE59803985D1 (de) 2002-06-06
HU9801886D0 (en) 1998-10-28
US5986048A (en) 1999-11-16
TR199801587A3 (tr) 1999-03-22
JPH11130798A (ja) 1999-05-18
DK0980874T3 (da) 2002-08-19
US20020156234A1 (en) 2002-10-24
HU228161B1 (en) 2013-01-28
EP0906918A2 (de) 1999-04-07
HK1119449A1 (en) 2009-03-06
HUP9801886A2 (hu) 1999-01-28
ES2177178T3 (es) 2002-12-01
HK1061870A1 (en) 2004-10-08
CA2245151C (en) 2009-10-06
CA2245151A1 (en) 1999-02-18
HUP9801886A3 (en) 1999-06-28
RU2205836C2 (ru) 2003-06-10
HK1018464A1 (en) 1999-12-24
ES2176870T3 (es) 2002-12-01
TR199801587A2 (xx) 1999-03-22
CN1483831B (zh) 2012-06-13
PT906918E (pt) 2002-10-31
US6727346B2 (en) 2004-04-27
HU228203B1 (en) 2013-01-28
HU0600287D0 (en) 2006-05-29
KR100537842B1 (ko) 2006-03-23
EP0980874B1 (de) 2002-05-02

Similar Documents

Publication Publication Date Title
CN1132845C (zh) 获得具有正确键合的胱氨酸键的胰岛素前体的改进的方法
CN1172811A (zh) 增强了锌结合力的胰岛素衍生物
CN1193042C (zh) 用于改进胰岛素和胰岛素类似物的制备方法的c肽
CN101068833A (zh) 产生羧基端酰胺化肽的方法
CN1529757A (zh) 用于向细菌培养物上清液中分泌目的蛋白质的融合蛋白质
CN1265143A (zh) 通过内源基因活化制备促红细胞生成素
CN1152955C (zh) 生产蛋白酶的方法
CN1303299A (zh) 关于肽合成的方法以及组合物
CN1916017A (zh) 生产疏水多肽、蛋白质或肽的方法
CN1049166A (zh) Magainin肽的取代类似物
CN1111909A (zh) 新多肽及编码该多肽的dna
CN1213146C (zh) 从新的融合蛋白制造重组胰岛素的方法
CN1765929A (zh) 含有肽载体和表皮生长因子的融合蛋白和核酸及其用途
CN1219883C (zh) 改造合成的苏云金芽孢杆菌杀虫晶体蛋白基因CrylC*
CN1798569A (zh) 用于治疗1型糖尿病的治疗性疫苗组合物
CN101041828A (zh) 家蚕基因及其在真核细胞中的表达和应用
CN1865283A (zh) 固相多肽合成鲑鱼降钙素的制备方法
CN1829798A (zh) 蛋白酶、编码该蛋白酶的dna、蛋白酶的制备方法
CN1046559A (zh) 制备胰高血糖素的方法
HK1018464B (en) Improved process for obtaining insulin precursors haveing correctly bonded cystine bridges
CN1298742C (zh) 一种适合于高效表达的融合蛋白及其生产方法
CN1186448C (zh) 重组人α胸腺素原－白介素2基因及其表达、应用
CN1256431C (zh) 重组人甲状旁腺激素基因、其表达载体及重组人甲状旁腺激素蛋白的制备方法
CN1273600C (zh) 红豆杉紫杉烷c13－侧链－n－苯甲酰转运酶蛋白及其编码基因
CN1547610A (zh) 用于生长激素高表达的dna及其应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Applicant after: Awentis Medicines Deutschland GmbH

Applicant before: German Beh Chester Marie

Applicant before: Searl Oro Co. Ltd.

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: HOECHST MARION GERMANY; MOSHIER LTD. TO: AVENTIS PHARMACY (GERMANY)INTERNATIONAL CO., LTD.

C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: SANOFI- AVENTIS GERMAN CO., LTD.

Free format text: FORMER NAME OR ADDRESS: AVENTIS PHARMACY (GERMANY)INTERNATIONAL CO., LTD.

CP03 Change of name, title or address

Address after: Frankfurt, Federal Republic of Germany

Patentee after: Aventis Pharma GmbH

Address before: Frankfurt, Federal Republic of Germany

Patentee before: Awentis Medicines Deutschland GmbH

CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20031231